Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP303c with Simmitinib or Irinotecan Liposomes in HER2+ Gastric Cancer
NCT06577376Phase 2Not yet recruiting
- Sponsor
- Shanghai Runshi Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 2, randomised, open-label trial of DP303c in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (6 arms), sponsored by Shanghai Runshi Pharmaceutical Technology Co., Ltd. Primary endpoints: Dose-limiting toxicity at 36 months, Adverse events at 36 months and 2 more. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
DP303c
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06577376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06577376.